Protalix and Secarna Collaborate on Rare Renal Disease Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Protalix and Secarna Pharmaceuticals announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide therapies against multiple targets for rare renal indications. As part of the collaboration, Protalix has selected pharmaceutical targets with fundamental biological roles in rare renal indications and Secarna will apply OligoCreator, its proprietary AI-empowered oligonucleotide discovery and development platform, to design and profile ASO candidates against those targets. By jointly applying their research and development expertise, it is the companies' goal to advance the programs from preclinical stage to clinical trials. Under the terms of the collaboration agreement, Secarna grants Protalix an option to an exclusive, worldwide milestone and royalty bearing license to further develop, market and commercialize therapeutic programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLX
Wall Street analysts forecast PLX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.140
Low
12.00
Averages
12.00
High
12.00
Current: 2.140
Low
12.00
Averages
12.00
High
12.00
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Protalix BioTherapeutics Q1 2026 Earnings Call Insights
- Milestone Revenue: Protalix received a $25 million milestone payment from Chiesi in Q1 2026, driving total revenue to $33.8 million, indicating positive progress in product promotion and expected to enhance future cash flow and market confidence.
- Financial Outlook: The company reaffirmed its 2026 total revenue guidance of $78 million to $83 million, with Elfabrio revenues anticipated at $33 million to $35 million and Elelyso revenues at $20 million to $23 million, reflecting management's confidence in future performance.
- Increased R&D Spending: R&D expenses rose to $5.4 million in Q1, up from $3.5 million in the prior year, primarily for preparations for the Phase II RELEASE study of PRX-115, demonstrating the company's ongoing investment in new product development.
- Net Income Turnaround: The quarter saw a net income of $18.3 million, or $0.23 per share, compared to a net loss of $3.6 million in the same period last year, showcasing a significant improvement in the company's financial health and boosting investor confidence in its long-term growth potential.
See More
Protalix BioTherapeutics Reaffirms 2026 Revenue Guidance
- Earnings Highlights: Protalix BioTherapeutics reported a Q1 GAAP EPS of $0.22 with revenues of $33.75 million, reflecting a remarkable 233.8% year-over-year growth, indicating strong market momentum for the company.
- 2026 Revenue Outlook: The company reaffirms its 2026 revenue expectations, projecting total revenues to range from $78 million to $83 million, including a $25 million milestone already received, showcasing confidence in future performance.
- Sales Forecast: For 2026, Protalix anticipates Elfabrio sales to generate approximately $33 million to $35 million, while Elelyso sales are expected to range from $20 million to $23 million, reflecting positive market demand expectations for its products.
- Competitive Market Challenges: Despite facing oral competition pressures for Elfabrio, Protalix aims to bolster investor confidence through milestone-backed revenue guidance, demonstrating its strategic resilience in a competitive biopharmaceutical landscape.
See More
Protalix BioTherapeutics Reports Q1 Earnings
- Earnings Performance: Protalix BioTherapeutics reported a profit of $18.3 million in Q1, translating to earnings of $0.22 per share, indicating robust growth in the drug development sector and boosting investor confidence.
- Revenue Growth: The company posted quarterly revenue of $33.8 million, reflecting an increase compared to the previous year, which demonstrates sustained demand for its products in the market and further solidifies its market position.
- Full-Year Revenue Outlook: Protalix expects full-year revenue to range between $78 million and $83 million, signaling strong confidence in future business development, which may attract more investor interest.
- Market Reaction: With the growth in earnings and revenue, Protalix's stock is likely to experience positive impacts, enhancing investor expectations for its future performance and further driving the company's competitiveness in the biopharmaceutical industry.
See More
Protalix BioTherapeutics Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Protalix BioTherapeutics (PLX) is set to announce its Q1 2023 earnings on May 13 before market open, with consensus EPS estimate at -$0.01 and revenue expected at $11.47 million, reflecting a 13.5% year-over-year growth.
- Historical Performance: Over the past year, PLX has beaten EPS estimates 50% of the time and has achieved a 100% success rate in beating revenue estimates, indicating a stable performance that may bolster investor confidence.
- Future Guidance: Protalix targets revenue between $78 million and $83 million for 2026, contingent on achieving EU milestones, which could positively impact the company's long-term growth trajectory if realized.
- Competitive Pressure: Despite Protalix's solid revenue performance, its product Elfabrio faces challenges from oral competitors, which may affect its market share and future financial outcomes.
See More
Protalix BioTherapeutics Reports FY 2025 Results with Mixed Performance
- Product Sales Performance: Protalix reported product sales of $51.8 million for FY 2025, a slight decline from $53.0 million in 2024, primarily due to reduced sales to partner Chiesi, although increased demand from Pfizer and Brazil's Fiocruz partially offset this decline.
- Financial Performance: The company reported a net loss of $6.6 million, or $(0.08) per share, compared to a net income of $2.9 million, or $0.04 per share, in 2024, indicating a significant deterioration in profitability.
- Cash Flow Position: As of year-end 2025, Protalix had cash and cash equivalents of $30.3 million, with expectations to strengthen to about $50.0 million by April 2026, supported by a $25 million milestone payment from Chiesi.
- Future Outlook: Management projects 2026 revenues between $78 million and $83 million, with Elfabrio sales expected to contribute $33.0 million to $35.0 million and Elelyso sales forecasted at $20.0 million to $23.0 million, indicating ongoing growth potential in rare disease therapies.
See More
Protalix BioTherapeutics Q4 2025 Earnings Call Insights
- EU Dosing Approval: Protalix announced the European Commission's approval of Elfabrio's 2 mg/kg every 4-week dosing regimen, enhancing treatment options for adult Fabry disease patients and expected to significantly improve long-term management, thereby strengthening the company's competitive position in the market.
- Revenue Growth Outlook: Management projects total revenues for 2026 to range from $78 million to $83 million, including a $25 million milestone payment from Chiesi, with expected revenue from Chiesi growing over 50%, which will further solidify the company's profitability profile.
- Increased R&D Investment: R&D expenses reached $19.6 million in 2025, primarily driven by investments in the PRX-115 RELEASE study, which is anticipated to enhance the company's competitive edge in the uncontrolled gout market, with management expressing optimism about the product's prospects.
- Strong Cash Position: As of December 31, 2025, Protalix's cash and cash equivalents totaled $30.3 million, with expectations to reach approximately $50 million by early 2026, providing ample financial support for executing strategies and clinical trials.
See More
Protalix BioTherapeutics Q1 2026 Earnings Call Insights
- Milestone Revenue: Protalix received a $25 million milestone payment from Chiesi in Q1 2026, driving total revenue to $33.8 million, indicating positive progress in product promotion and expected to enhance future cash flow and market confidence.
- Financial Outlook: The company reaffirmed its 2026 total revenue guidance of $78 million to $83 million, with Elfabrio revenues anticipated at $33 million to $35 million and Elelyso revenues at $20 million to $23 million, reflecting management's confidence in future performance.
- Increased R&D Spending: R&D expenses rose to $5.4 million in Q1, up from $3.5 million in the prior year, primarily for preparations for the Phase II RELEASE study of PRX-115, demonstrating the company's ongoing investment in new product development.
- Net Income Turnaround: The quarter saw a net income of $18.3 million, or $0.23 per share, compared to a net loss of $3.6 million in the same period last year, showcasing a significant improvement in the company's financial health and boosting investor confidence in its long-term growth potential.
See More
Protalix BioTherapeutics Reaffirms 2026 Revenue Guidance
- Earnings Highlights: Protalix BioTherapeutics reported a Q1 GAAP EPS of $0.22 with revenues of $33.75 million, reflecting a remarkable 233.8% year-over-year growth, indicating strong market momentum for the company.
- 2026 Revenue Outlook: The company reaffirms its 2026 revenue expectations, projecting total revenues to range from $78 million to $83 million, including a $25 million milestone already received, showcasing confidence in future performance.
- Sales Forecast: For 2026, Protalix anticipates Elfabrio sales to generate approximately $33 million to $35 million, while Elelyso sales are expected to range from $20 million to $23 million, reflecting positive market demand expectations for its products.
- Competitive Market Challenges: Despite facing oral competition pressures for Elfabrio, Protalix aims to bolster investor confidence through milestone-backed revenue guidance, demonstrating its strategic resilience in a competitive biopharmaceutical landscape.
See More
Protalix BioTherapeutics Reports Q1 Earnings
- Earnings Performance: Protalix BioTherapeutics reported a profit of $18.3 million in Q1, translating to earnings of $0.22 per share, indicating robust growth in the drug development sector and boosting investor confidence.
- Revenue Growth: The company posted quarterly revenue of $33.8 million, reflecting an increase compared to the previous year, which demonstrates sustained demand for its products in the market and further solidifies its market position.
- Full-Year Revenue Outlook: Protalix expects full-year revenue to range between $78 million and $83 million, signaling strong confidence in future business development, which may attract more investor interest.
- Market Reaction: With the growth in earnings and revenue, Protalix's stock is likely to experience positive impacts, enhancing investor expectations for its future performance and further driving the company's competitiveness in the biopharmaceutical industry.
See More
Protalix BioTherapeutics Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Protalix BioTherapeutics (PLX) is set to announce its Q1 2023 earnings on May 13 before market open, with consensus EPS estimate at -$0.01 and revenue expected at $11.47 million, reflecting a 13.5% year-over-year growth.
- Historical Performance: Over the past year, PLX has beaten EPS estimates 50% of the time and has achieved a 100% success rate in beating revenue estimates, indicating a stable performance that may bolster investor confidence.
- Future Guidance: Protalix targets revenue between $78 million and $83 million for 2026, contingent on achieving EU milestones, which could positively impact the company's long-term growth trajectory if realized.
- Competitive Pressure: Despite Protalix's solid revenue performance, its product Elfabrio faces challenges from oral competitors, which may affect its market share and future financial outcomes.
See More
Protalix BioTherapeutics Reports FY 2025 Results with Mixed Performance
- Product Sales Performance: Protalix reported product sales of $51.8 million for FY 2025, a slight decline from $53.0 million in 2024, primarily due to reduced sales to partner Chiesi, although increased demand from Pfizer and Brazil's Fiocruz partially offset this decline.
- Financial Performance: The company reported a net loss of $6.6 million, or $(0.08) per share, compared to a net income of $2.9 million, or $0.04 per share, in 2024, indicating a significant deterioration in profitability.
- Cash Flow Position: As of year-end 2025, Protalix had cash and cash equivalents of $30.3 million, with expectations to strengthen to about $50.0 million by April 2026, supported by a $25 million milestone payment from Chiesi.
- Future Outlook: Management projects 2026 revenues between $78 million and $83 million, with Elfabrio sales expected to contribute $33.0 million to $35.0 million and Elelyso sales forecasted at $20.0 million to $23.0 million, indicating ongoing growth potential in rare disease therapies.
See More
Protalix BioTherapeutics Q4 2025 Earnings Call Insights
- EU Dosing Approval: Protalix announced the European Commission's approval of Elfabrio's 2 mg/kg every 4-week dosing regimen, enhancing treatment options for adult Fabry disease patients and expected to significantly improve long-term management, thereby strengthening the company's competitive position in the market.
- Revenue Growth Outlook: Management projects total revenues for 2026 to range from $78 million to $83 million, including a $25 million milestone payment from Chiesi, with expected revenue from Chiesi growing over 50%, which will further solidify the company's profitability profile.
- Increased R&D Investment: R&D expenses reached $19.6 million in 2025, primarily driven by investments in the PRX-115 RELEASE study, which is anticipated to enhance the company's competitive edge in the uncontrolled gout market, with management expressing optimism about the product's prospects.
- Strong Cash Position: As of December 31, 2025, Protalix's cash and cash equivalents totaled $30.3 million, with expectations to reach approximately $50 million by early 2026, providing ample financial support for executing strategies and clinical trials.
See More
